BMY News and Press, Bristol-Myers Squibb Company From 06/07/24

2024-06-07 15:00:58 ET More on the markets Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) SPY: 2 Options To Balance Out A Highly Concentrated Index Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity Citi – ...

2024-06-07 10:32:06 ET Summary Halozyme Therapeutics, Inc. raised both its full year 2024 financial guidance and 5-year financial outlook on Thursday, sending the stock 12% higher. Halozyme Therapeutics continues to execute well, is buying back a significant amount of its own stoc...

2024-06-06 22:31:45 ET More on Geron Geron Corporation: A High-Risk Deal With A Good Chance Of Success Geron Corporation (GERN) Q1 2024 Earnings Call Transcript Geron: FDA PDUFA Review With Continued Imetelstat Advancement Geron GAAP EPS of -$0.09 beats by $0...

2024-06-06 12:05:40 ET More on Replimune Group Replimune: Continuing To Justify The Bear Thesis (For Now) Seeking Alpha’s Quant Rating on Replimune Group Historical earnings data for Replimune Group Financial information for Replimune Group R...

2024-06-06 10:47:18 ET More on 2seventy bio 2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround Bristol-Myers posts Q1 beat despite growth headwinds Bristol Myers, 2seventy bio's Abecma a...

2024-06-06 09:00:00 ET Summary The Dividend Harvesting Portfolio generated over $100 of dividend income in May, with a return on invested capital of 14.14%. The portfolio's diversification helped stabilize market conditions, with a 1.45% growth in profitability despite market decl...

2024-06-05 09:15:55 ET More on Bristol-Myers Squibb Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Gener...

2024-06-04 11:20:58 ET Summary Schrödinger is a hybrid biopharma company specializing in physics-based computational chemistry and traditional drug development. The company aims to utilize computational methods to create better drug candidates and improve strategic decision-m...

2024-06-04 10:26:59 ET More on Bristol-Myers Squibb Company Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be...

2024-06-04 09:00:00 ET Summary Bristol-Myers Squibb has experienced significant declines in its stock price, but I believe it has potential for future growth. The risks of investing in BMY include underperformance compared to the market and potential setbacks in its drug pipeline....